ProCE Banner Activity

ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors

Slideset Download
Conference Coverage
In the ATLAS-A/B trial, prophylactic treatment with fitusiran resulted in significant reductions in annualized bleeding rates compared with on-demand factor replacement therapy in patients with hemophilia A or B and no inhibitors.

Released: December 16, 2021

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo Inc


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation